Flexible ureteroscopy to monitor upper tract urothelial carcinoma
Official title: Flexible Ureterorenoscopy for Surveillance of Upper Tract Urothelial Carcinoma - A Pilot Study
Run by Chinese University of Hong Kong · NCT07557563 · Data updated 2026-11-12
A small, forward-looking study will test whether doing flexible ureteroscopy under local anesthesia is safe and feasible for people who have had kidney-sparing treatment for upper tract urothelial carcinoma.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 10 (estimated) |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong) |
| Status | Recruiting |
| Started | October 1, 2025 |
| Main results expected | December 31, 2027 |
| Study ends | March 31, 2028 |
| Registry record updated | October 27, 2026 |
| Trial ID | NCT07557563 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 years or older who have had kidney-sparing surgery for upper tract urothelial carcinoma and consent to undergo surveillance flexible ureteroscopy.
✕Probably not a fit
Patients with contraindications to local anesthesia, active anticoagulation without safe cessation, or structural abnormalities on the test side may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective single-arm pilot investigates the safety and practicality of performing surveillance flexible ureteroscopy of the upper urinary tract under local anesthesia in an ambulatory setting. Consecutive patients who previously underwent kidney-sparing surgery will be screened for eligibility. The study will collect perioperative outcomes, patient-reported outcomes, complications, and a cost-effectiveness analysis to determine feasibility for routine use. The procedure under local anesthesia is intended to minimize anesthesia exposure while enabling regular surveillance. No comparator group is included in this early feasibility assessment.
Why it matters
Potential benefit: If successful, this approach could offer a less invasive, chairside surveillance option with reduced anesthesia requirements for patients after kidney-sparing treatment.
How similar studies have gone: Previous studies in similar endoscopic surveillance approaches have shown safety and feasibility in related urothelial settings, supporting exploration in this context.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Aged 18 years or older 2. Capable of giving informed consent 3. Having undergone an kidney-sparing surgery (endoscopic operation or segmental ureterectomy) Exclusion Criteria: 1. Allergy to transurethral lidocaine jelly 2. On anticoagulation or anti-platelet medication with contraindications for cessation prior to the procedure 3. Structural abnormalities in the upper urinary tract on the intended side of examination
Where it's running
-
Prince of Wales Hospital
Hong Kong, Hong Kong Recruiting
Study contacts
- Principal investigator: Yuen Chun Jeremy TEOH, MD — Chinese University of Hong Kong
- Study coordinator: Ho Ming Chris WONG, MBChB
- Email: chriswong@surgery.cuhk.edu.hk
- Phone: 35052625
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Urinary Cell-Free DNA Test for Urothelial Cancer Origin
This study tests a urine-based cell-free DNA test to help diagnose urothelial cancer and identify whether it started in the bladder or upper urinary tract in adults.
-
Blood test for detecting tumor DNA in bladder and upper tract cancer
A blood test that looks for tumor DNA in people with muscle-invasive bladder cancer or upper tract urothelial cancer is being tested to see if it matches what’s found in tumor tissue and if it can help track recurrence or remission over two years.
-
Non-invasive urine test to screen for urothelial cancer in adults with blood in urine
A noninvasive urine test is being used to see if it can correctly identify urothelial cancer in adults who have blood in urine and a suspicious imaging finding.
-
Disitamab Vedotin Plus Radiotherapy for HER2-Expressing Upper Tract Urothelial Carcinoma After Surgery
This study tests whether disitamab vedotin with radiotherapy can improve outcomes for people with HER2-expressing upper tract urothelial carcinoma after radical surgery who can’t receive cisplatin.
-
Dual-target Nectin-4 and HER2 CAR-NK therapy for advanced urothelial carcinoma
This treatment will try dual-target CAR-NK cells that recognize Nectin‑4 and HER2 in adults with relapsed or metastatic urothelial carcinoma after standard therapies.
-
Kidney-and-ureter removal with or without template lymph node removal for high-risk upper tract urothelial cancer
This trial will test whether adding a template lymph node removal to standard kidney-and-ureter surgery helps people with high-risk upper tract urothelial cancer live longer without the cancer coming back.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.